Trial Profile
Prospective observational study on the key drug selection in advanced/recurrent EGFR mutation-positive non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.